Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00329147 |
The purpose of this study is to evaluate the effects of multiple doses of DVS SR and paroxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
Condition | Intervention | Phase |
---|---|---|
Depression |
Drug: desvenlafaxine SR Drug: desipramine Drug: paroxetine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Pharmacokinetics Study |
Official Title: | A Randomized, Open-Label, Cross-Over Drug Interaction Study to Evaluate the Effects of Desvenlafaxine (DVS SR) and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 3151A1-900 |
Study First Received: | May 23, 2006 |
Last Updated: | December 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00329147 |
Health Authority: | United States: Food and Drug Administration |
Healthy Subjects Major Depressive Disorder Depression |
Depression O-desmethylvenlafaxine Mental Disorders Mood Disorders Healthy Depressive Disorder, Major |
Desipramine Depressive Disorder Paroxetine Serotonin Behavioral Symptoms |
Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic Uptake Inhibitors Physiological Effects of Drugs Psychotropic Drugs Enzyme Inhibitors |
Serotonin Uptake Inhibitors Pharmacologic Actions Antidepressive Agents, Tricyclic Serotonin Agents Therapeutic Uses Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |